POC Test Based on Quantum Dots Detects Antibody Responses
|
By LabMedica International staff writers Posted on 31 Oct 2019 |

Image: The Holomics Reader HRDR-300 mobile device was used to measure fluorescent intensity of the quantum dots complex after lateral migration of patient serum (Photo courtesy of Medical College of Georgia).
Point-of-care (POC) assays, which can be performed at or near the site of care with a rapid turnaround time, are pivotal to transforming global disease control efforts, particularly in resource-constrained settings where access to laboratory facilities is limited.
Cysticercosis is an infection caused by the larval form of the pork tapeworm Taenia solium. When larval cysts form in the human brain known as neurocysticercosis (NCC), they can result in seizures and other neurologic disorders. NCC affects those living in endemic and non-endemic countries, with an estimated more than 18,000 hospitalizations in the USA between 2003 and 2012.
Medical scientists at the Medical College of Georgia (Athens, GA, USA) and their international colleagues examined 112 positive human sera from patients with neurocysticercosis (NCC) including samples from 18 patients with single viable cyst, 71 patients with two or more viable cysts, and 23 patients with subarachnoid (racemose) cysts. Definitive diagnosis of the subject was established by computed-tomography and/or magnetic resonance imaging.
To test the specificity of the assay, the team evaluated a panel of serum samples obtained from 24 patients with other infections and 128 serum samples from persons in the USA and Egypt who had not traveled outside their country, and therefore were presumed negative for cysticercosis. The scientists developed a novel and portable fluorescent sensor that integrates a lateral flow assay with a quantum dot (Qdots) label and a mobile phone reader for detection of specific antibodies in human serum. They evaluated the utility of this assay to test for antibodies to the Taenia solium rT24H antigen.
The team read the lateral flow assay after 30 minutes, using the Holomics Reader HRDR-30. The investigators reported that the assay specificity in the negative panel was 99% (95%–100%) while assay sensitivity was 89% (79%–95%) in NCC patients with two or more viable cysts. The assay has performance characteristics similar to those of traditional platforms for the detection of NCC and shows promise as a mobile phone reader-based point-of-care test for antibody detection. The study was published on October 7, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Medical College of Georgia
Cysticercosis is an infection caused by the larval form of the pork tapeworm Taenia solium. When larval cysts form in the human brain known as neurocysticercosis (NCC), they can result in seizures and other neurologic disorders. NCC affects those living in endemic and non-endemic countries, with an estimated more than 18,000 hospitalizations in the USA between 2003 and 2012.
Medical scientists at the Medical College of Georgia (Athens, GA, USA) and their international colleagues examined 112 positive human sera from patients with neurocysticercosis (NCC) including samples from 18 patients with single viable cyst, 71 patients with two or more viable cysts, and 23 patients with subarachnoid (racemose) cysts. Definitive diagnosis of the subject was established by computed-tomography and/or magnetic resonance imaging.
To test the specificity of the assay, the team evaluated a panel of serum samples obtained from 24 patients with other infections and 128 serum samples from persons in the USA and Egypt who had not traveled outside their country, and therefore were presumed negative for cysticercosis. The scientists developed a novel and portable fluorescent sensor that integrates a lateral flow assay with a quantum dot (Qdots) label and a mobile phone reader for detection of specific antibodies in human serum. They evaluated the utility of this assay to test for antibodies to the Taenia solium rT24H antigen.
The team read the lateral flow assay after 30 minutes, using the Holomics Reader HRDR-30. The investigators reported that the assay specificity in the negative panel was 99% (95%–100%) while assay sensitivity was 89% (79%–95%) in NCC patients with two or more viable cysts. The assay has performance characteristics similar to those of traditional platforms for the detection of NCC and shows promise as a mobile phone reader-based point-of-care test for antibody detection. The study was published on October 7, 2019, in the journal PLOS Neglected Tropical Diseases.
Related Links:
Medical College of Georgia
Latest Microbiology News
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
- New Test Measures How Effectively Antibiotics Kill Bacteria
- New Antimicrobial Stewardship Standards for TB Care to Optimize Diagnostics
- New UTI Diagnosis Method Delivers Antibiotic Resistance Results 24 Hours Earlier
- Breakthroughs in Microbial Analysis to Enhance Disease Prediction
- Blood-Based Diagnostic Method Could Identify Pediatric LRTIs
- Rapid Diagnostic Test Matches Gold Standard for Sepsis Detection
- Rapid POC Tuberculosis Test Provides Results Within 15 Minutes
- Rapid Assay Identifies Bloodstream Infection Pathogens Directly from Patient Samples
- Blood-Based Molecular Signatures to Enable Rapid EPTB Diagnosis
- 15-Minute Blood Test Diagnoses Life-Threatening Infections in Children
- High-Throughput Enteric Panels Detect Multiple GI Bacterial Infections from Single Stool Swab Sample
- Fast Noninvasive Bedside Test Uses Sugar Fingerprint to Detect Fungal Infections
Channels
Clinical Chemistry
view channel
Existing Hospital Analyzers Can Identify Fake Liquid Medical Products
Counterfeit and substandard medicines remain a serious global health threat, with World Health Organization estimates suggesting that 10.5% of medicines in low- and middle-income countries are either fake... Read more
Rapid Blood Testing Method Aids Safer Decision-Making in Drug-Related Emergencies
Acute recreational drug toxicity is a frequent reason for emergency department visits, yet clinicians rarely have access to confirmatory toxicology results in real time. Instead, treatment decisions are... Read moreMolecular Diagnostics
view channel
New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids
Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more
AI-Powered Liquid Biopsy Classifies Pediatric Brain Tumors with High Accuracy
Liquid biopsies offer a noninvasive way to study cancer by analyzing circulating tumor DNA in body fluids. However, in pediatric brain tumors, the small amount of ctDNA in cerebrospinal fluid has limited... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreMicrobiology
view channel
Rapid Test Promises Faster Answers for Drug-Resistant Infections
Drug-resistant pathogens continue to pose a growing threat in healthcare facilities, where delayed detection can impede outbreak control and increase mortality. Candida auris is notoriously difficult to... Read more
CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
Antibiotic resistance has accelerated into a global health crisis, with projections estimating more than 10 million deaths per year by 2050 as drug-resistant “superbugs” continue to spread.... Read more
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read morePathology
view channel
Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples
Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
New AI-Driven Platform Standardizes Tuberculosis Smear Microscopy Workflow
Sputum smear microscopy remains central to tuberculosis treatment monitoring and follow-up, particularly in high‑burden settings where serial testing is routine. Yet consistent, repeatable bacillary assessment... Read more
AI Tool Uses Blood Biomarkers to Predict Transplant Complications Before Symptoms Appear
Stem cell and bone marrow transplants can be lifesaving, but serious complications may arise months after patients leave the hospital. One of the most dangerous is chronic graft-versus-host disease, in... Read moreTechnology
view channel
Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
More than 7 million Americans live with Alzheimer’s disease, and related health and long-term care costs are projected to reach nearly USD 400 billion in 2025. The disease has no cure, and symptoms often... Read more
AI-Powered Biomarker Predicts Liver Cancer Risk
Liver cancer, or hepatocellular carcinoma, causes more than 800,000 deaths worldwide each year and often goes undetected until late stages. Even after treatment, recurrence rates reach 70% to 80%, contributing... Read more
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreIndustry
view channel
QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio
QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more







